Somnia Therapeutics
- Company typePrivate
- Founded2019
- HeadquartersCresskill, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
Somnia Therapeutics firmographics
Firmographics- Name
- Somnia Therapeutics
- Legal name
- Somnia Therapeutics LLC
- Website
- https://somniatx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Where Somnia Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cresskill
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Somnia Therapeutics business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Drug Sales: Pre-revenue biopharmaceutical company. Future revenue expected from commercialization of oral drug candidate for OSA treatment upon regulatory approval. Revenue model will likely involve prescription drug sales through pharmacy channels.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Somnia Therapeutics product offering
Product offeringCore offering
Somnia Therapeutics is a pre-IND biopharmaceutical company developing a single oral drug therapy for the treatment of obstructive sleep apnea (OSA). The drug candidate is an oral pill taken before bedtime that targets the acetylcholine pathway to increase upper airway muscle tonicity, preventing airway collapse during sleep. The product is based on repositioning an existing prescription drug originally approved for an unrelated orphan disorder, reformulated at a significantly lower dose for OSA. Clinical proof-of-concept studies have demonstrated statistically significant reductions in apnea events.
Product overview
Somnia Therapeutics is developing a single oral drug therapy for obstructive sleep apnea (OSA). The drug candidate targets the acetylcholine pathway to increase upper airway muscle tonicity and is administered as a pill before bedtime. The drug is based on an existing prescription drug for an unrelated orphan disorder, reformulated with a significantly lower dose than the current allowed daily dosage. Clinical proof-of-concept studies have demonstrated statistically significant reductions in apnea events (p < 0.05) in all treated patients.
Differentiator
Problem solved
Functional benefit
Products and services
- Somnia Oral Drug for Obstructive Sleep Apnea
Quantifiable outcome
- 30% median reduction in AHI over entire sleep period
- +4 more outcomes
Companies that use Somnia Therapeutics
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Somnia Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Somnia Therapeutics partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights4 records
Somnia Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Jazz Pharmaceuticals: Jazz markets Xywav and other sleep-disordered-breathing and CNS products. Its commercial footprint in sleep medicine makes it a relevant comparator for downstream commercialization of an OSA drug.
- ResMed: ResMed is the dominant CPAP and sleep-respiratory device manufacturer. It represents the entrenched device incumbent whose adherence failures create the opportunity Somnia is pursuing.
- Inspire Medical Systems: Inspire markets an implantable neurostimulation device for OSA patients who fail CPAP. It is a key non-pharmaceutical incumbent competing for the same moderate-to-severe OSA patient that Somnia is targeting with a pill.
- Eli Lilly: Eli Lilly's tirzepatide (Zepbound) received FDA approval for moderate-to-severe OSA with obesity in 2024, establishing GLP-1 therapy as a credible OSA pharmacotherapy. As a large-cap incumbent, Lilly sets the efficacy and commercial benchmark Somnia will need to differentiate against.
- Philips Respironics: Philips Respironics is a leading CPAP and sleep-apnea device franchise. Like ResMed, it defines the standard-of-care that any oral OSA pharmacotherapy must displace on convenience and adherence.
Direct peers
- Apnimed: Apnimed is developing oral pharmacotherapies (e.g., AD109, aroxybutynin/patomilidine combinations) specifically for obstructive sleep apnea. It is the most directly comparable peer to Somnia given its oral-dosing, OSA-only therapeutic focus, and similar clinical-stage status.
Emerging players
- NLS Pharmaceutics: NLS Pharmaceutics is an early-stage company developing CNS and sleep-disordered-breeding therapeutics. It overlaps with Somnia as a small-cap emerging player pursuing sleep-related drug indications.
- Avadel Pharmaceuticals: Avadel received FDA approval for Lumryz, an extended-release sodium oxybate for excessive daytime sleepiness in narcolepsy. It is an emerging sleep-medicine specialty pharma with relevant late-stage development and commercialization experience.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Somnia Therapeutics social profiles
Digital presenceSomnia Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Somnia Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Somnia Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Somnia Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Somnia Therapeutics
What does Somnia Therapeutics do?
Somnia Therapeutics is a pre-IND biopharmaceutical company developing a single oral drug therapy for the treatment of obstructive sleep apnea (OSA). The drug candidate is an oral pill taken before bedtime that targets the acetylcholine pathway to increase upper airway muscle tonicity, preventing airway collapse during sleep. The product is based on repositioning an existing prescription drug originally approved for an unrelated orphan disorder, reformulated at a significantly lower dose for OSA. Clinical proof-of-concept studies have demonstrated statistically significant reductions in apnea events.
Is Somnia Therapeutics a public or private company?
Somnia Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Somnia Therapeutics founded?
Somnia Therapeutics was founded in 2019. It employs 1 to 10 people.
Where is Somnia Therapeutics based?
Somnia Therapeutics is headquartered in Cresskill, United States, in the North America region.
How does Somnia Therapeutics make money?
One revenue line is on record: pharmaceutical Drug Sales.
Who are Somnia Therapeutics's main competitors?
Broad incumbents on record are Jazz Pharmaceuticals, ResMed, Inspire Medical Systems, Eli Lilly and Philips Respironics. Apnimed is listed as a direct peer. Emerging players are NLS Pharmaceutics and Avadel Pharmaceuticals.
Does Somnia Therapeutics have an API?
No public API is recorded for Somnia Therapeutics.